<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Measles: Clinical manifestations, diagnosis, treatment, and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Measles: Clinical manifestations, diagnosis, treatment, and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Measles: Clinical manifestations, diagnosis, treatment, and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hayley Gans, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Yvonne A Maldonado, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Measles is a highly contagious viral illness that occurs worldwide. The infection is characterized by fever, malaise, cough, coryza, and conjunctivitis, followed by exanthem. Following exposure, approximately 90 percent of susceptible individuals will develop measles. The period of contagiousness is estimated to be from five days before the appearance of the rash to four days afterward. The illness may be transmitted in public spaces, even in the absence of person-to-person contact.</p><p>Measles virus infection can cause a variety of clinical syndromes, including [<a href="#rid1">1-4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Classic measles infection in immunocompetent individuals</p><p class="bulletIndent1"><span class="glyph">●</span>Modified measles infection in patients with pre-existing but incompletely protective anti-measles antibody</p><p class="bulletIndent1"><span class="glyph">●</span>Atypical measles infection in patients immunized with the killed virus vaccine</p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic syndromes following measles infection, including acute disseminated encephalomyelitis and subacute sclerosing panencephalitis</p><p class="bulletIndent1"><span class="glyph">●</span>Severe measles infection especially in immunocompromised individuals</p><p class="bulletIndent1"><span class="glyph">●</span>Complications of measles including secondary infection, giant cell pneumonia, and measles inclusion body encephalitis</p><p></p><p>The clinical manifestations, diagnosis, and treatment of measles will be reviewed here. Issues related to epidemiology, transmission, and prevention of measles virus infection are discussed separately. (See  <a class="medical medical_review" href="/d/html/3019.html" rel="external">"Measles: Epidemiology and transmission"</a> and  <a class="medical medical_review" href="/d/html/3893.html" rel="external">"Measles, mumps, and rubella immunization in adults"</a> and  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3"><span class="h2">Stages of infection</span><span class="headingEndMark"> — </span>Classic measles virus infection can be subdivided into the following clinical stages: incubation, prodrome, exanthem, and recovery [<a href="#rid3">3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Incubation period – The incubation period for measles is 6 to 21 days (median 13 days) [<a href="#rid5">5</a>]; it begins after virus entry via the respiratory mucosa or conjunctivae. The virus replicates locally, spreads to regional lymphatic tissues, and is then thought to disseminate to other reticuloendothelial sites via the bloodstream, which is considered the first viremia [<a href="#rid6">6</a>]. The period of contagiousness is estimated to be from five days before the appearance of rash to four days afterward. Infected individuals are characteristically asymptomatic during the incubation period, although some have been reported to experience transient respiratory symptoms, fever, or rash [<a href="#rid7">7,8</a>].</p><p></p><p class="bulletIndent1">The dissemination of measles virus due to viremia, with associated infection of endothelial, epithelial, monocyte, and macrophage cells, may explain the variety of clinical manifestations and complications that can occur with measles virus infection. A second viremia occurs several days after the first, coinciding with the appearance of symptoms signaling the beginning of the prodromal phase.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prodrome – The prodrome usually lasts for two to four days but may persist for as long as eight days [<a href="#rid9">9</a>]; it is defined by the appearance of symptoms that typically include fever, malaise, and anorexia, followed by conjunctivitis, coryza, and cough. The severity of conjunctivitis is variable and may also be accompanied by lacrimation or photophobia [<a href="#rid7">7</a>]. The respiratory symptoms result from mucosal inflammation from viral infection of epithelial cells. Fever is typically present. Various fever patterns have been described, and fever as high as 40ºC can occur. The prodromal symptoms typically intensify a few days before the exanthem appears [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Enanthem – Approximately 48 hours prior to onset of the exanthem, patients may develop an enanthem characterized by Koplik spots; these are 1 to 3 mm whitish, grayish, or bluish elevations with an erythematous base, typically seen on the buccal mucosa opposite the molar teeth, though they can spread to cover the buccal and labial mucosa  (<a class="graphic graphic_picture graphicRef57571" href="/d/graphic/57571.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef131901" href="/d/graphic/131901.html" rel="external">picture 2</a>) as well as the hard and soft palate [<a href="#rid10">10</a>]. They have been described as "grains of salt on a red background" [<a href="#rid8">8</a>]. Koplik spots may coalesce and generally last 12 to 72 hours [<a href="#rid11">11</a>]. Koplik spots often begin to slough when the exanthem appears.</p><p></p><p class="bulletIndent2">It is important to search carefully for Koplik spots in patients with suspected measles, since they can improve the accuracy of clinical diagnosis [<a href="#rid12">12</a>]. However, this enanthem does not appear in all patients with measles.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exanthem – The exanthem of measles arises approximately two to four days after onset of fever; it consists of an erythematous, maculopapular, blanching rash, which classically begins on the face and spreads cephalocaudally and centrifugally to involve the neck, upper trunk, lower trunk, and extremities  (<a class="graphic graphic_picture graphicRef57093 graphicRef57803" href="/d/graphic/57093.html" rel="external">picture 3A-B</a>). Early on, the lesions are blanching; in the later stages, they are not  (<a class="graphic graphic_picture graphicRef57803" href="/d/graphic/57803.html" rel="external">picture 3B</a>). The rash may include petechiae; in severe cases, it may appear hemorrhagic [<a href="#rid13">13-15</a>]. In children, the extent of the rash and degree of confluence generally correlate with the severity of the illness. The palms and soles are rarely involved. The cranial to caudal progression of the rash is characteristic of measles but is not pathognomonic [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">Other characteristic findings during the exanthematous phase include lymphadenopathy, high fever (peaking two to three days after appearance of rash), pronounced respiratory signs including pharyngitis, and nonpurulent conjunctivitis. Uncommonly, patients with severe measles develop generalized lymphadenopathy and splenomegaly [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">Clinical improvement typically ensues within 48 hours of the appearance of the rash. After three to four days, the rash darkens to a brownish color (in patients of White European descent though not patients of African descent) and begins to fade, followed by fine desquamation in the more severely involved areas. The rash usually lasts six to seven days and fades in the order it appeared [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recovery and immunity – Cough may persist for one to two weeks after measles. The occurrence of fever beyond the third to fourth day of rash suggests a measles-associated complication. (See <a class="local">'Complications'</a> below.)</p><p></p><p class="bulletIndent1">Both humoral and cellular measles-specific immunity are important for viral clearance and lasting protective immunity [<a href="#rid3">3</a>]. Children with defects in humoral immunity, such as agammaglobulinemia, generally recover from measles, while individuals with T cell deficiencies often have severe measles infection and high mortality rates [<a href="#rid16">16-18</a>].</p><p></p><p class="bulletIndent1">Immunity after measles virus infection is thought to be lifelong, although there are rare reports of measles reinfection [<a href="#rid19">19-21</a>]. A measles surveillance program conducted in the mid-1960s, for example, identified measles in a 16-year-old female with a prior history of measles at age 8 [<a href="#rid19">19</a>]. A rise in anti-measles immunoglobulin (Ig)G but not IgM was observed in this individual, suggesting an anamnestic response. (See <a class="local">'Modified measles'</a> below.)</p><p></p><p class="bulletIndent1">Measles virus infection is associated with immunosuppression that can persist. (See <a class="local">'Immune suppression and secondary infection'</a> below.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Clinical variants</span></p><p class="headingAnchor" id="H5"><span class="h3">Modified measles</span><span class="headingEndMark"> — </span>Modified measles is an attenuated infection that occurs in individuals with pre-existing measles immunity (either via wild-type disease or vaccination). It is similar to classic measles except the clinical manifestations are generally milder and the incubation period is longer (17 to 21 days) [<a href="#rid9">9,22</a>]. Individuals with modified measles are not highly contagious [<a href="#rid23">23,24</a>].</p><p>Individuals with nonprotective immunity to measles can develop modified measles; nonprotective immunity may occur in one of the following ways:</p><p class="bulletIndent1"><span class="glyph">●</span>Transplacental transfer of anti-measles antibody from mother to infant. This antibody is generally cleared by three to nine months of age [<a href="#rid7">7</a>]; clearance is earlier among infants born to vaccinated women than infants born to women with history of natural infection [<a href="#rid25">25</a>]. When antibody titers reach levels that are not considered protective, the infant is at risk for measles infection, but low antibody levels may prevent severe disease.</p><p class="bulletIndent1"><span class="glyph">●</span>Receipt of immunoglobulin.</p><p class="bulletIndent1"><span class="glyph">●</span>Measles vaccination resulting in antibody titers lower than those considered seroprotective [<a href="#rid26">26</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Prior history of measles [<a href="#rid20">20</a>]. (See <a class="local">'Stages of infection'</a> above.)</p><p></p><p class="headingAnchor" id="H6"><span class="h3">Atypical measles</span><span class="headingEndMark"> — </span>Atypical measles refers to measles virus infection among individuals immunized with the killed virus vaccine, which was used in the United States between 1963 and 1967; atypical measles is now rare. The killed virus vaccine sensitized the recipient to measles virus antigens without providing full protection [<a href="#rid6">6</a>].</p><p>Individuals with atypical measles develop high fever and headache 7 to 14 days after exposure to measles. Atypical measles is characterized by higher and more prolonged fever [<a href="#rid27">27</a>]. A maculopapular rash develops two to three days later, beginning on the extremities (instead of the head as seen with typical measles) and spreading to the trunk. The rash may involve the palms and soles and tends to spare the upper chest, neck, and head [<a href="#rid7">7</a>]. The rash may be vesicular, petechial, purpuric, or urticarial; it may have a hemorrhagic component. The distribution and varied appearance of the rash can make diagnosis difficult.</p><p>A dry cough and pleuritic chest pain are often present; pneumonitis can be severe [<a href="#rid7">7</a>]. Chest radiograph typically demonstrates bilateral pulmonary nodules and hilar lymphadenopathy [<a href="#rid10">10</a>]. Atypical measles often results in severe illness; many individuals develop respiratory distress. Some individuals develop peripheral edema, hepatosplenomegaly, and/or neurologic symptoms such as paresthesias or hyperesthesias [<a href="#rid7">7</a>].</p><p>Laboratory findings can include elevated serum aminotransferases [<a href="#rid10">10</a>]. Atypical measles is associated with a characteristic antibody pattern: before or at the onset of the exanthem, the titer is usually &lt;1:5 but, by day 10 of illness, the titer is typically ≥1:1280. The height and rapidity of antibody titer rise is much higher than in primary natural measles infection [<a href="#rid7">7</a>].</p><p>The pathogenesis of atypical measles is not entirely understood. Studies in macaques have shown that the formalin-inactivated measles vaccine induces low avidity, short-lived antibodies against the hemagglutinin protein but not the fusion protein, allowing cell-to-cell viral spread with no cytotoxic T cell immunity. Upon exposure to wild-type measles, the poorly neutralizing antibodies form complexes with the measles antigen, resulting in immune complex deposition, vasculitis, and pneumonitis [<a href="#rid28">28</a>].</p><p>Individuals with atypical measles do not appear to transmit measles virus to others [<a href="#rid29">29</a>].</p><p>The differential diagnosis of atypical measles is broad. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Thrombocytopenia, leukopenia, and T cell cytopenia may be observed during measles infection [<a href="#rid7">7</a>]. Chest radiography may demonstrate interstitial pneumonitis [<a href="#rid10">10</a>].</p><p>Biopsy samples of lymphoid tissues before the appearance of the exanthem may demonstrate reticuloendothelial giant cells. Histologic analysis of enanthem or exanthem and cytologic examination of nasal secretions may also demonstrate epithelial giant cells [<a href="#rid10">10</a>].</p><p>Histologic evaluation of conjunctival, nasopharyngeal, or buccal epithelial cells may demonstrate giant cells with inclusions  (<a class="graphic graphic_picture graphicRef54083" href="/d/graphic/54083.html" rel="external">picture 4</a>); these cells may also be present in urine [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H9"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>One or more complications occur in approximately 30 percent of measles cases [<a href="#rid6">6</a>]. Diarrhea is the most common complication [<a href="#rid6">6</a>]; most deaths are due to respiratory tract complications or encephalitis. Otitis media occurs in 5 to 10 percent of cases and is more common in younger individuals. The risk of complications is increased in resource-limited settings, where the case fatality rate is 4 to 10 percent [<a href="#rid30">30</a>].</p><p>Groups at increased risk for complications of measles are described below. (See <a class="local">'Groups at risk for complications'</a> below.)</p><p class="headingAnchor" id="H367342723"><span class="h2">Immune suppression and secondary infection</span><span class="headingEndMark"> — </span>Measles virus infection can lead to immune suppression and secondary infections, which are important components of measles-related morbidity and mortality [<a href="#rid31">31,32</a>]. Secondary and coinfections may include bacteremia, pneumonia, gastroenteritis and otitis media [<a href="#rid33">33</a>]. Pathogens involved include viruses (eg, parainfluenza virus and adenovirus), and bacteria (eg, <em>Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes</em>) [<a href="#rid34">34</a>]. Tuberculosis reactivation in the setting of recent measles infection has also been described [<a href="#rid10">10,29</a>]. Measles associated immune defects may account for increased mortality for up to three years following infection [<a href="#rid35">35</a>].</p><p>Several immune alterations have been associated with measles virus infection, including T cell lymphopenia with depletion of T-dependent areas of lymph nodes and spleen, cutaneous anergy [<a href="#rid36">36</a>], diminished in vitro T cell proliferation with mitogens or alloantigens, and diminished antibody production [<a href="#rid17">17,18,37,38</a>].</p><p>As an example of the impact on humoral immunity, one study of 77 unvaccinated children found that 11 to 73 percent of the measured array of antibodies to other pathogens was lost following natural measles infection [<a href="#rid39">39</a>]. In another report, genetic sequencing of B cells harvested from patients before and after measles virus infection suggested incomplete restoration of the naive B cell pool; depletion of B memory cells was also identified [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H69934411"><span class="h2">Gastrointestinal</span><span class="headingEndMark"> — </span>Diarrhea is the most common complication; it occurs in approximately 8 percent of cases [<a href="#rid6">6</a>]. Other gastrointestinal complications include gingivostomatitis, gastroenteritis, hepatitis, mesenteric lymphadenitis, and appendicitis. In resource-limited settings, measles-induced stomatitis and diarrhea can lead to diminished nutritional status [<a href="#rid7">7,10</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Pulmonary</span><span class="headingEndMark"> — </span>Pneumonia is the most common cause of measles-associated death in children; it occurs in approximately 6 percent of cases [<a href="#rid6">6</a>]. Respiratory tract infections occur most frequently among patients &lt;5 years and &gt;20 years of age.</p><p>Pulmonary complications of measles virus infection include bronchopneumonia, laryngotracheobronchitis (croup), and bronchiolitis [<a href="#rid8">8,31</a>]. Measles has also been associated with development of bronchiectasis, which can predispose to recurrent respiratory infections [<a href="#rid31">31</a>]. Bacterial superinfection may occur in up to 5 percent of cases.</p><p>In one retrospective study of measles deaths in South Africa, 85 percent of cases were attributed to pneumonia (due to viral or bacterial infection) [<a href="#rid31">31</a>]. In a series of 182 cases of measles-associated pneumonia, bacterial pathogens included <em>Streptococcus pneumoniae</em>, <em>Streptococcus pyogenes</em>, <em>Haemophilus influenzae</em>, and <em>Staphylococcus aureus</em> [<a href="#rid7">7,8,41</a>]. Coinfection with other viruses was also documented, especially parainfluenza (25 percent of patients) and adenovirus (19 percent of patients), but also with cytomegalovirus, enterovirus, influenza, and respiratory syncytial virus.</p><p class="headingAnchor" id="H11"><span class="h2">Neurologic</span><span class="headingEndMark"> — </span>Neurologic complications associated with measles include encephalitis, acute disseminated encephalomyelitis and subacute sclerosing panencephalitis.</p><p>Acute measles-induced encephalopathy has been described in the setting of human immunodeficiency virus infection; this manifestation is rare [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Encephalitis</span><span class="headingEndMark"> — </span>Encephalitis occurs in up to 1 per 1000 measles cases. It usually appears within a few days of the rash, typically day 5 (range 1 to 14 days); symptoms may include fever, headache, vomiting, stiff neck, meningeal irritation, drowsiness, convulsions, and coma [<a href="#rid6">6</a>]. Acute measles encephalitis may also occur in the absence of rash [<a href="#rid43">43</a>]. Analysis of cerebrospinal fluid is notable for pleocytosis (predominantly lymphocytes), elevated protein concentration, and normal glucose concentration. Approximately 25 percent of children have neurodevelopmental sequelae; rapidly progressive and fatal disease occurs in about 15 percent of cases [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H13"><span class="h3">Acute disseminated encephalomyelitis</span><span class="headingEndMark"> — </span>Acute disseminated encephalomyelitis (ADEM) is a demyelinating disease that occurs in about 1 per 1000 measles cases. ADEM is thought to be a postinfectious autoimmune response; it may be triggered by a number of infectious causes [<a href="#rid8">8,10,44</a>]. (See  <a class="medical medical_review" href="/d/html/6184.html" rel="external">"Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p>ADEM presents during the recovery phase of measles, typically within two weeks of the exanthem [<a href="#rid10">10,44,45</a>]. In contrast, subacute sclerosing panencephalitis (SSPE) generally presents years after initial infection. (See <a class="local">'Subacute sclerosing panencephalitis'</a> below.)</p><p>Clinical manifestations of ADEM include fever, headache, neck stiffness, seizures, and mental status changes such as confusion, somnolence, or coma [<a href="#rid29">29,46</a>]. Other manifestations may include ataxia, myoclonus, choreoathetosis, and signs of myelitis, such as paraplegia, quadriplegia, sensory loss, loss of bladder and bowel control, and back pain [<a href="#rid46">46</a>]. Analysis of cerebrospinal fluid generally demonstrates a lymphocytic pleocytosis and elevated protein concentration. (See  <a class="medical medical_review" href="/d/html/1284.html" rel="external">"Viral encephalitis in adults", section on 'Viral versus postinfectious encephalitis'</a>.)</p><p>ADEM following measles infection is associated with a 10 to 20 percent mortality [<a href="#rid44">44</a>]; this is higher than mortality from ADEM due to other causes (up to 7 percent) [<a href="#rid47">47</a>]. Residual neurologic abnormalities are common among survivors, including behavior disorders, cognitive deficits, and epilepsy [<a href="#rid44">44,46</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Subacute sclerosing panencephalitis</span><span class="headingEndMark"> — </span>SSPE is a fatal, progressive degenerative disease of the central nervous system that usually occurs 7 to 10 years after natural measles virus infection. Its pathogenesis is not well understood but may involve persistent infection with a genetic variant of measles virus within the central nervous system [<a href="#rid10">10,48</a>].</p><p>The incidence of SSPE increases when vaccination rates fall [<a href="#rid49">49,50</a>]. Between 1960 and 1974, the risk of SSPE was 8.5 cases per million cases of natural measles infection. Between 1970 and 1980, the risk of SSPE fell to 0.06 cases per million; the decline paralleled the decline of measles cases as a result of vaccination (with a lag time of several years) [<a href="#rid49">49</a>].</p><p>Between 1989 and 1991, during a resurgence of measles infection in the United States, the risk of SSPE was estimated to be approximately 200 per million (eg, more than 10-fold higher than the historical estimates); however, due to likely under-reporting of measles cases, the true risk was thought to be about half of this estimate [<a href="#rid51">51</a>]. Subsequently, a study including cases of measles diagnosed in California between 1998 and 2015 noted that the risk of SSPE among children with measles infection who were less than five years of age at the time of the initial infection was approximately 730 per million (1:1367); the risk for development of SSPE among children whose measles infection occurred prior to 12 months of age was approximately 1640 per million (1:609) [<a href="#rid52">52</a>].</p><p>In general, patients with SSPE are ≤20 years and become ill 7 to 10 years after natural measles infection [<a href="#rid51">51</a>]. Measles infection at an early age is a risk factor for SSPE; about half of patients with SSPE had measles before the age of two years [<a href="#rid53">53</a>]. The risk of SSPE after measles immunization is thought to be lower than after natural measles infection; according to the United States Centers for Disease Control and Prevention, the risk of SSPE following vaccination is ≤1/12 the risk of SSPE following infection [<a href="#rid7">7,49</a>]. </p><p>It is controversial whether vaccination can cause SSPE. In one review evaluating the effect of measles vaccination on the epidemiology of SSPE, SSPE was eliminated once wild-type virus was eliminated; even among patients with measles that was thought to be vaccine-induced, wild-type virus was isolated by biopsy [<a href="#rid54">54</a>].</p><p>SSPE has been divided into the following stages [<a href="#rid48">48,53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage I – Stage I consists of insidious development of neurologic symptoms such as personality changes, lethargy, difficulty in school, and strange behavior. Stage I may last from weeks to years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage II – Stage II is characterized by myoclonus, worsening dementia, and long-tract motor or sensory disease. The patient eventually develops a highly characteristic form of myoclonus in which massive myoclonic jerks occur approximately every 5 to 10 seconds. Stage II usually lasts 3 to 12 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stages III and IV – Stages III and IV are characterized by further neurologic deterioration with eventual flaccidity or decorticate rigidity and symptoms and signs of autonomic dysfunction. Myoclonus is absent. Stage IV is a vegetative state. Death usually occurs during stage IV but is possible in any of the stages [<a href="#rid55">55</a>].</p><p></p><p>The rate of progression is variable. Stabilization at one stage for a period of time can occur, though patients tend to progress from one stage to the next [<a href="#rid56">56</a>]. Some patients have a remitting and relapsing course. Seizures can occur in any of the stages.</p><p>The serum anti-measles antibody concentration is elevated, and cerebrospinal fluid analysis shows elevated protein concentration and detectable anti-measles antibody [<a href="#rid7">7,10</a>].</p><p>Electroencephalogram (EEG) during stage II may demonstrate bursts of high-voltage complexes (300 to 1500 microvolts) of two- to three-per-second delta waves (slow waves) and sharp waves. These complexes last 0.5 to 3 seconds and occur every 3 to 20 seconds [<a href="#rid57">57-59</a>]. Each complex is followed by a relatively flat pattern [<a href="#rid58">58</a>]. These EEG findings are characteristic of SSPE and may be pathognomonic [<a href="#rid48">48,58</a>]. The EEG may also be abnormal in the other stages of SSPE [<a href="#rid48">48</a>].</p><p>Computed tomography of the brain may demonstrate atrophy and scarring [<a href="#rid48">48</a>]. Magnetic resonance imaging of the brain may be normal. In one report (18)F-fluorodeoxyglucose positron emission tomography and magnetic resonance spectroscopy revealed substantial functional abnormalities [<a href="#rid60">60</a>]; these could be useful techniques for the early detection of SSPE and for assessing the specific brain areas affected in the early stages of SSPE (when MRI findings are likely to be normal).</p><p>The relentless and fatal course of SSPE underscores the importance of measles vaccination, not only for prevention of measles but also for prevention of the severe neurologic sequelae that can ensue. </p><p class="headingAnchor" id="H16"><span class="h2">Other complications</span><span class="headingEndMark"> — </span>Ocular complications of measles include keratitis (a common cause of blindness) and corneal ulceration [<a href="#rid7">7,10,61</a>].</p><p>Cardiac complications of measles include myocarditis and pericarditis.</p><p class="headingAnchor" id="H20"><span class="h1">GROUPS AT RISK FOR COMPLICATIONS</span><span class="headingEndMark"> — </span>Groups at increased risk for complications of measles include immunocompromised patients, pregnant women, individuals with <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> deficiency or poor nutritional status, and individuals at the extremes of age [<a href="#rid7">7,29,62-64</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Immunocompromised patients</span><span class="headingEndMark"> — </span>Patients with defects in cell-mediated immunity (eg, AIDS, lymphoma or other malignancies, and those receiving T cell-suppressive medications) are at risk for severe, progressive measles virus infection [<a href="#rid62">62</a>].</p><p>The clinical presentation of measles in immunocompromised hosts may be atypical [<a href="#rid62">62</a>]. Exanthem may be absent, evanescent, or severe and desquamative; purpura has also been described. Therefore, a high level of suspicion should be present when an immunocompromised host presents with pneumonia or encephalitis, particularly after measles exposure and despite history of previous immunization [<a href="#rid62">62,65,66</a>].</p><p>Some unique measles-associated manifestations have been described in immunocompromised patients; these include giant cell pneumonia and measles inclusion body encephalitis.</p><p class="bulletIndent1"><span class="glyph">●</span>Giant cell pneumonia is characterized by multinucleated giant cells in lung tissue. It can develop in immunocompromised patients after classic measles infection or after a vague prodromal illness that may not include an exanthem [<a href="#rid7">7</a>]. In patients without a rash, lung biopsy may be required to make the diagnosis  (<a class="graphic graphic_picture graphicRef54083" href="/d/graphic/54083.html" rel="external">picture 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measles inclusion body encephalitis (MIBE) is characterized by histopathologic evidence of inclusions in neurons and glial cells. Patients present one to six months after exposure to measles with seizures, mental status changes, and myoclonus. MIBE may sometimes present in conjunction with giant cell pneumonia. The pathogenesis of this disorder is uncertain [<a href="#rid10">10</a>].</p><p></p><p>Children with human immunodeficiency virus (HIV) infection may present with measles at an earlier age than HIV-uninfected children (11 versus 15 months) [<a href="#rid67">67,68</a>].</p><p>Measles virus infection may have a transient suppressive effect on HIV replication [<a href="#rid69">69,70</a>]; it has been hypothesized that measles infection results in immune activation with factors that are suppressive to HIV viral replication. In a study of 93 HIV-infected children hospitalized with measles, the median plasma HIV ribonucleic acid (RNA) level was lower than the median plasma HIV RNA level among HIV-infected children without acute illness (5339 versus 228,454 copies/mL); median levels rose to 60,121 at discharge and 387,148 copies/mL at one month follow-up, respectively [<a href="#rid69">69</a>].</p><p>Serology may not be useful for diagnosis of measles in immunocompromised patients because of deficient antibody synthesis [<a href="#rid29">29</a>]. In these cases, alternative diagnostic approaches should be taken, as described below. Biopsy of involved tissues may be necessary for a definitive diagnosis. (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H24"><span class="h2">Pregnant women</span><span class="headingEndMark"> — </span>Measles during pregnancy is associated with increased risk for serious maternal and fetal complications [<a href="#rid71">71-75</a>]. In one study including 55 pregnant women with measles in Namibia, measles-related complications included diarrhea (60 percent), pneumonia (40 percent), and encephalitis (5 percent) [<a href="#rid75">75</a>]. Of the 42 pregnancies with known outcomes, 60 percent had at least one adverse maternal, fetal, or neonatal outcome, and 12 percent of women died. Risk for low birthweight, spontaneous abortion, intrauterine fetal death, and maternal death was significantly increased. Another study noted an increased incidence of premature birth [<a href="#rid72">72</a>].</p><p>Maternal measles virus infection at the time of delivery is not always associated with neonatal infection. Congenital measles (defined by the appearance of measles rash within 10 days of birth) and postnatally acquired measles (defined as appearance of measles rash within 14 to 30 days of birth) are associated with a spectrum of illnesses ranging from mild to severe disease [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H69935375"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of measles should be considered in a patient presenting with a febrile rash illness and clinically compatible symptoms (eg, cough, coryza, and conjunctivitis), especially in the setting of recent exposure to an individual with a febrile rash illness or travel to an area of high measles prevalence, particularly in the absence of measles immunity. Patients being evaluated for measles should be isolated. </p><p>The diagnosis of measles virus infection is usually made based on at least one of the following: positive serologic test for serum measles IgM antibody, significant rise in measles IgG antibody between acute and convalescent titers, isolation of measles virus in culture, or detection of measles virus RNA by reverse transcription polymerase chain reaction (RT-PCR). The approach to diagnosis differs depending on the regional prevalence of measles:</p><p class="bulletIndent1"><span class="glyph">●</span>Low measles prevalence (high measles vaccine coverage) – In regions of low measles prevalence, cases of suspected or confirmed measles should be reported to the local health authorities, who can provide guidance on specimen collection for diagnosis as well as infection control interventions. In general, it is useful to obtain three samples from patients with suspected measles infection: a serum sample for measles IgM, a throat or nasopharyngeal swab for viral culture, and a urine sample for viral culture. RT-PCR is useful where available. In the setting of diagnostic uncertainty, the diagnosis may be confirmed by evaluation of paired acute and convalescent sera for anti-measles virus IgG; at least fourfold increase in anti-measles antibody titer is indicative of infection [<a href="#rid76">76,77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High measles prevalence (low measles vaccine coverage) – In regions of high measles prevalence, the World Health Organization advocates use of serum IgM as the standard test to confirm a diagnosis of measles. However, the anti-measles virus IgM assay should be interpreted with caution, as false-positive and false-negative results have been reported [<a href="#rid10">10,76</a>]. In one study, at least some false-positive results were found to result from human parvovirus B19 IgM [<a href="#rid78">78</a>].</p><p></p><p>Serology (anti-measles IgM) is the most common laboratory method used for diagnosis of measles virus infection. The detection of measles virus-specific IgM in serum or oral fluid is diagnostic of acute infection, although false positives may rarely occur and the sensitivity of individual assays varies [<a href="#rid6">6,79</a>]. Anti-measles IgM is generally detectable three days after the appearance of the exanthem; it may be undetectable on the day the exanthem appears [<a href="#rid76">76</a>]. IgM is usually undetectable approximately 30 days after the exanthem. Anti-measles IgG is generally undetectable up to 7 days after rash onset but subsequently peaks about 14 days after the exanthem appears [<a href="#rid76">76</a>].</p><p>Measles virus RNA can be detected in heparinized blood, nasopharyngeal aspirates, throat swabs, and urine by real time reverse transcription polymerase chain reaction (rRT–PCR) and conventional, endpoint RT-PCR [<a href="#rid80">80</a>]. Viral RNA is usually present for approximately three days after rash onset.</p><p>Culturing virus from peripheral blood mononuclear cells, respiratory secretions, conjunctival swabs, or urine can also establish the diagnosis of measles [<a href="#rid10">10</a>]. Measles virus has been isolated from nasopharyngeal secretions during the prodromal phase [<a href="#rid7">7</a>]. However, culture of the virus requires special facilities. Viral isolates are important for molecular epidemiologic surveillance and can be performed in state public health laboratories or the United States Centers for Disease Control and Prevention.</p><p class="headingAnchor" id="H69933723"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of measles depends on the clinical stage.</p><p>Dengue fever may be mistaken for measles during the prodromal period or after the appearance of exanthem and should be considered in the setting of relevant epidemiologic exposure. Dengue may be diagnosed via serologic testing. (See  <a class="medical medical_review" href="/d/html/3025.html" rel="external">"Dengue virus infection: Clinical manifestations and diagnosis"</a>.)</p><p>During the prodromal period, the differential diagnosis includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Common respiratory viruses of childhood – These include rhinoviruses, parainfluenza, influenza, adenovirus, and respiratory syncytial virus infections. Fever due to measles infection is typically more pronounced than fever due to other respiratory viruses; these may be distinguished via nasal swab for polymerase chain reaction [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/5978.html" rel="external">"The common cold in children: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fordyce spots – Koplik spots can be mistaken for Fordyce spots (tiny yellow-white granules sometimes found on the buccal or lip mucosa resulting from benign ectopic sebaceous glands) [<a href="#rid81">81</a>]. Unlike Koplik spots, Fordyce spots do not occur on an erythematous mucosal background [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/5572.html" rel="external">"Oral lesions"</a>.)</p><p></p><p>Once an exanthem has appeared, the differential diagnosis includes  (<a class="graphic graphic_table graphicRef102213" href="/d/graphic/102213.html" rel="external">table 1</a>) [<a href="#rid7">7,10,29,82</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Viral causes of rash in children – These include varicella, roseola (human herpesvirus 6 infection), erythema infectiosum (parvovirus B19 infection), enterovirus (hand-foot-and-mouth disease), and rubella. Measles can usually be distinguished clinically by the characteristic progression of the rash, its subsequent brownish coloration, blanching on pressure, and other clinical manifestations (especially coryza and conjunctivitis) [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/d/html/6035.html" rel="external">"Roseola infantum (exanthem subitum)"</a> and  <a class="medical medical_review" href="/d/html/8272.html" rel="external">"Clinical manifestations and diagnosis of parvovirus B19 infection"</a> and  <a class="medical medical_review" href="/d/html/2693.html" rel="external">"Enterovirus and parechovirus infections: Clinical features, laboratory diagnosis, treatment, and prevention"</a> and  <a class="medical medical_review" href="/d/html/8301.html" rel="external">"Rubella"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Group A <em>Streptococcus</em> infection – Manifestations of group A <em>Streptococcus</em> (GAS) that resemble measles include scarlet fever and toxic shock syndrome. Scarlet fever is diagnosed based on clinical manifestations including rash (coarse, sandpaper-like, erythematous, blanching) in association with pharyngitis; toxic shock syndrome is based on isolation of GAS from a normally sterile site (or for a probable case, if GAS is isolated from a nonsterile site), together with hypotension and organ system dysfunction. (See  <a class="medical medical_review" href="/d/html/8046.html" rel="external">"Complications of streptococcal tonsillopharyngitis", section on 'Scarlet fever'</a> and  <a class="medical medical_review" href="/d/html/3162.html" rel="external">"Invasive group A streptococcal infection and toxic shock syndrome: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug eruption – An exanthematous drug eruption can resemble the rash associated with measles; it may be distinguished based on history of recent drug exposure and resolution of the rash after drug withdrawal. (See  <a class="medical medical_review" href="/d/html/15762.html" rel="external">"Exanthematous (maculopapular) drug eruption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meningococcemia – Clinical manifestations of meningococcemia may include petechial rash in association with fever, nausea, vomiting, headache, altered mental status, and hemodynamic instability. The diagnosis is established via culture. (See  <a class="medical medical_review" href="/d/html/1300.html" rel="external">"Clinical manifestations of meningococcal infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rocky Mountain spotted fever – Clinical manifestations of Rocky Mountain spotted fever include fever, headache, and maculopapular rash in the setting of tick exposure; the rash typically begins on the extremities and subsequently spreads to the trunk. The diagnosis is established via serology or skin biopsy. (See  <a class="medical medical_review" href="/d/html/7904.html" rel="external">"Clinical manifestations and diagnosis of Rocky Mountain spotted fever"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infectious mononucleosis – Typical features of infectious mononucleosis include fever, pharyngitis, adenopathy, and fatigue. A generalized rash (maculopapular, urticarial, or petechial) is occasionally seen; a maculopapular rash often occurs following administration of certain antibiotics (eg, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>). (See  <a class="medical medical_review" href="/d/html/8318.html" rel="external">"Infectious mononucleosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Mycoplasma pneumoniae</em> – Clinical manifestations of <em>M. pneumoniae </em>infection include respiratory tract infection, which may occur in association with a mild erythematous maculopapular or vesicular rash. The diagnosis can be difficult to establish and most treatment is empiric. (See  <a class="medical medical_review" href="/d/html/6989.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunoglobulin A vasculitis (IgAV; Henoch-Schönlein purpura [HSP]) – Clinical manifestations of IgAV (HSP) include palpable purpura, arthritis, abdominal pain, and renal disease. The diagnosis is based on clinical manifestations and/or biopsy. (See  <a class="medical medical_review" href="/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Kawasaki disease – Clinical manifestations of Kawasaki disease include fever and mucocutaneous involvement including conjunctivitis, erythema of the lips and oral mucosa, rash, and cervical lymphadenopathy. The diagnosis is based on clinical criteria  (<a class="graphic graphic_table graphicRef67711" href="/d/graphic/67711.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/6417.html" rel="external">"Kawasaki disease: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multisystem inflammatory syndrome in children (MIS-C) – This condition occurs following infection or exposure to COVID-19 and causes fever, abdominal pain, rash, and conjunctivitis. The diagnosis is based on clinical criteria. (See  <a class="medical medical_review" href="/d/html/128190.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H2086563653"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatment of measles is supportive; there is no specific antiviral therapy approved for treatment of measles. There is a role for <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> in certain settings, discussed below. Supportive therapy includes antipyretics, fluids, and treatment of bacterial superinfections, such as bacterial pneumonia and otitis media. Treatment of other complications, such as seizures and respiratory failure, may also be necessary.</p><p>Antibiotic prophylaxis during measles epidemics may prevent complications; further study is needed [<a href="#rid83">83,84</a>].</p><p class="headingAnchor" id="H1141311546"><span class="h2">Vitamin A</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">Vitamin A</a> deficiency contributes to delayed recovery and to risk of complications associated with measles infection. In addition, vitamin A levels fall during measles; in children with underlying vitamin A deficiency, measles can result in xerophthalmia, a spectrum of eye disease [<a href="#rid1">1,3</a>]. Xerophthalmia is characterized by pathologic dryness of the conjunctiva and cornea, caused by inadequate function of the lacrimal glands, and is manifested by Bitot spots  (<a class="graphic graphic_picture graphicRef72148" href="/d/graphic/72148.html" rel="external">picture 5</a>) (areas of abnormal squamous cell proliferation and keratinization of the conjunctiva), progressing to corneal xerosis (dryness) and keratomalacia (softening)  (<a class="graphic graphic_picture graphicRef72297" href="/d/graphic/72297.html" rel="external">picture 6</a>). (See  <a class="medical medical_review" href="/d/html/2571.html" rel="external">"Overview of vitamin A", section on 'Clinical manifestations'</a>.)</p><p><a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">Vitamin A</a> supplementation may be beneficial for reducing measles severity and risk of complications. Some data suggest that administration of vitamin A to children &lt;2 years of age with measles may be associated with reduced mortality [<a href="#rid85">85,86</a>]. </p><p>In one review including eight randomized trials and more than 2500 children with measles (including six studies in Africa, one study in Japan, and one study in England), <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> supplementation did not reduce mortality; however, among three studies including approximately 300 children &lt;2 years and who received two doses of vitamin A (200,000 international units administered once daily for two consecutive days), lower mortality was observed (1.9 versus 10.7 percent) [<a href="#rid86">86</a>]. </p><p>In resource-rich settings, data on use of <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> for treatment of measles are limited; one study including 108 inpatient children in Italy did not observe a benefit to vitamin A administration [<a href="#rid87">87</a>].</p><p>For children with severe measles, we suggest administration of <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a>; this approach is in alignment with the United States Centers for Disease Control and Prevention, which favors administration of vitamin A to children hospitalized with severe measles [<a href="#rid2">2</a>]. In addition, for children in resource-limited settings with measles (regardless of severity), we suggest administration of vitamin A; this approach is in alignment with the World Health Organization guidance, which favors administration of vitamin A for children with acute measles [<a href="#rid1">1</a>]. </p><p>Dosing of <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> consists of oral administration once daily for two days, as follows [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Infants &lt;6 months of age − 50,000 international units</p><p class="bulletIndent1"><span class="glyph">●</span>Infants 6 to 11 months of age − 100,000 international units</p><p class="bulletIndent1"><span class="glyph">●</span>Children ≥12 months − 200,000 international units</p><p></p><p>For children with clinical signs and symptoms of severe <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> deficiency (such as xerophthalmia, keratitis, keratoconjunctivitis, corneal ulceration, or Bitot spots), a third dose of vitamin A should be administered four to six weeks later [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/2571.html" rel="external">"Overview of vitamin A", section on 'Deficiency'</a>.)</p><p class="headingAnchor" id="H2188937754"><span class="h2">Ribavirin</span><span class="headingEndMark"> — </span>Given the risk of measles-associated mortality among individuals in certain risk groups, we agree with some experts who favor use of <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> for treatment of measles pneumonia in patients &lt;12 months, patients ≥12 months with pneumonia requiring ventilatory support, and immunosuppressed patients. Ribavirin dosing consists of 15 to 20 mg/kg per day orally in two divided doses. The optimal duration of therapy is not known; a duration of five to seven days may be reasonable, guided by the patient's clinical status (respiratory symptoms and chest radiograph findings).</p><p>Measles virus is susceptible to <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> in vitro; data on clinical use of ribavirin are extremely limited [<a href="#rid88">88-92</a>]. In one trial including 100 children with measles treated with supportive care (with or without ribavirin), those who received ribavirin had a shorter duration of fever and constitutional symptoms [<a href="#rid88">88</a>]. In another report including six adults with severe measles pneumonitis treated with intravenous ribavirin, the five patients treated on day 2 to 5 of illness recovered; the patient treated on day 22 of illness did not recover [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H488451839"><span class="h2">Investigational therapies</span><span class="headingEndMark"> — </span>Agents for treatment subacute sclerosing panencephalitis (SSPE) have been evaluated with the goal of stabilization and delay of progression; these agents remain investigational. </p><p>Isoprinosine (<a class="drug drug_general" data-topicid="88326" href="/d/drug information/88326.html" rel="external">inosine pranobex</a>) has in vitro activity against mRNA viruses; it is administered orally and generally well tolerated. In one study including 98 individuals with SSPE, the probability of survival among treated patients at 2, 4, 6, and 8 years from onset of SSPE was 78, 69, 65, and 61 percent, compared with 38, 20, 14, and 8 percent in a composite control group [<a href="#rid93">93</a>]. </p><p>Interferon-alpha or beta has antiviral activity; it may be delivered both intrathecally and intravenously. Some data suggest transient survival benefit [<a href="#rid94">94</a>]. However, in one study including 67 individuals with SSPE, there was no difference in survival among patients treated with combination therapy (intraventricular interferon-alpha and isoprinosine) or isoprinosine monotherapy (35 percent); however, survival among the treated patients was higher than the historical control group (which reported spontaneous improvement in 5 to 10 percent of cases) [<a href="#rid95">95</a>].</p><p class="headingAnchor" id="H1850832089"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H2303347057"><span class="h2">Measles, mumps, and rubella vaccination</span><span class="headingEndMark"> — </span>Vaccination has led to interruption of measles virus transmission in the developed world and affords protection to unvaccinated individuals via herd immunity. To disrupt broad transmission, herd immunity must be maintained above 85 to 95 percent [<a href="#rid96">96</a>].</p><p>Issues related to vaccination for prevention of measles are discussed further separately. (See  <a class="medical medical_review" href="/d/html/3893.html" rel="external">"Measles, mumps, and rubella immunization in adults"</a> and  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents"</a>.)</p><p class="headingAnchor" id="H3612154638"><span class="h2">Infection control</span><span class="headingEndMark"> — </span>In the inpatient setting, airborne transmission precautions are indicated for four days after the onset of rash in otherwise healthy patients and for the duration of illness in immunocompromised patients [<a href="#rid97">97</a>]. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Airborne precautions'</a>.)</p><p>Susceptible individuals should not enter the room of patients with suspected or confirmed measles. Exposed susceptible individuals should be excluded from work from day 5 through day 21 after exposure. If the case is confirmed, even those who were vaccinated within 72 hours should be excluded.</p><p>In the outpatient setting, patients with febrile rash illness should be escorted to a separate waiting area or placed immediately in a private room, preferably at negative pressure relative to other patient care areas. Both patients and staff should wear appropriate masks/respirators (masks for patients to prevent generation of droplets, and respirators for staff to filter airborne particles, regardless of immunity status) [<a href="#rid98">98</a>]. If not admitted, patients should be told to remain in isolation at home through four days after rash onset. Measles virus can remain suspended in the air for up to two hours; therefore, the room occupied by a suspect case should not be used for two hours after the patient's departure.</p><p class="headingAnchor" id="H2531295210"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112441.html" rel="external">"Society guideline links: Measles"</a>.)</p><p class="headingAnchor" id="H10855819"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83973.html" rel="external">"Patient education: Measles (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syndrome and incubation period</strong> − Measles is a highly contagious viral illness that occurs worldwide. The infection is characterized by fever, malaise, cough, coryza, and conjunctivitis, followed by exanthem. Following exposure, approximately 90 percent of susceptible individuals develop measles. The period of contagiousness is estimated to be from five days before the appearance of the rash to four days afterward. The illness may be transmitted in public spaces, even in the absence of person-to-person contact. Patients being evaluated for measles should be isolated. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stages of infection</strong> − Classic measles infection in immunocompetent patients consists of the following clinical stages: incubation, prodrome, exanthem, and recovery. (See <a class="local">'Stages of infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Incubation</strong> <strong>–</strong> The incubation is 6 to 21 days (median 13 days).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prodrome</strong> <strong>–</strong> A two- to four-day prodrome phase is characterized by fever, malaise, and anorexia, followed by conjunctivitis, coryza, and cough. If present, Koplik spots  (<a class="graphic graphic_picture graphicRef57571" href="/d/graphic/57571.html" rel="external">picture 1</a>), an enanthem considered pathognomonic for measles infection, typically occurs approximately 48 hours prior to the exanthem.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Exanthem</strong> <strong>–</strong> The characteristic exanthem arises approximately two to four day after onset of fever; it consists of a red maculopapular rash, which classically begins on the face and head and spreads downward  (<a class="graphic graphic_picture graphicRef57093 graphicRef57803" href="/d/graphic/57093.html" rel="external">picture 3A-B</a>). Early on, the lesions are blanching; in later stages, they are not. The rash resolves in five to six days, fading in the order it appeared.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recovery</strong> <strong>–</strong> Cough may persist for one two weeks after measles. The occurrence of fever beyond the third to fourth day of rash suggests a measles-associated complication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical variants</strong> − Clinical variants include modified measles and atypical measles. Modified measles occurs in patients with preexisting but incompletely protective anti-measles antibody. Atypical measles occurs in patients immunized with the killed virus vaccine administered between 1963 and 1967 in the United States who are subsequently exposed to wild-type measles virus. (See <a class="local">'Clinical variants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> − The diagnosis of measles should be considered in a patient presenting with a febrile rash illness and clinically compatible symptoms. The approach to diagnosis differs depending on the regional prevalence of measles. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In regions of low measles prevalence, cases of suspected or confirmed measles should be reported to the local health authorities, who provide guidance on specimen collection for diagnosis as well as infection control interventions. In general, it is useful to obtain three samples from patients with suspected measles infection: a serum sample for measles immunoglobulin (Ig)M, a throat or nasopharyngeal swab for viral culture, and a urine sample for viral culture. In the setting of diagnostic uncertainty, the diagnosis may be confirmed by evaluation of paired acute and convalescent sera for anti-measles virus IgG; at least fourfold increase in anti-measles antibody titer is indicative of infection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In countries with high measles prevalence, the World Health Organization uses serum IgM as the standard test to confirm the diagnosis of measles. However, the anti-measles IgM assay should be interpreted with caution as false-positive and false-negative results have been reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complications of measles include secondary infections such as diarrhea and pneumonia. Complications of measles among immunocompromised individuals include giant cell pneumonia and measles inclusion body encephalitis. Acute primary measles encephalitis is another rare complication. Groups at increased risk for complications of measles include immunocompromised hosts, pregnant women, individuals with <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> deficiency or poor nutritional status, and individuals at the extremes of age. (See <a class="local">'Complications'</a> above and <a class="local">'Groups at risk for complications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neurologic syndromes following measles virus infection include acute disseminated encephalomyelitis (ADEM) and subacute sclerosing panencephalitis (SSPE). ADEM is a demyelinating disease that presents during the recovery phase of measles infection and is thought to be caused by a postinfectious autoimmune response. SSPE is a progressive degenerative disease of the central nervous system that generally occurs 7 to 10 years after natural measles infection; its pathogenesis may involve persistent infection with a genetic variant of measles virus within the central nervous system. (See <a class="local">'Acute disseminated encephalomyelitis'</a> above and <a class="local">'Subacute sclerosing panencephalitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> − The treatment of measles is largely supportive; in some cases, <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> and/or <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> may be beneficial. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supportive care</strong> <strong>−</strong> Supportive therapy includes antipyretics, fluids, and treatment of bacterial superinfections and other complications. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of </strong><a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> <strong>−</strong> For children with severe measles, we suggest administration of vitamin A (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). In addition, for children in resource-limited settings with measles (regardless of severity), we suggest administration of vitamin A (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Dosing is summarized above. (See <a class="local">'Vitamin A'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of </strong><a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> <strong>−</strong> For patients &lt;12 months with measles pneumonia, patients ≥12 months with measles pneumonia requiring ventilatory support, and immunosuppressed patients with measles, we suggest treatment with ribavirin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Dosing is summarized above. (See <a class="local">'Ribavirin'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges Jorge L Barinaga, MD, MS, and Paul R Skolnik, MD, FACP, FIDSA, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization. Guide for clinical case management and infection prevention and control during a measles outbreak https://apps.who.int/iris/handle/10665/331599 (Accessed on February 16, 2022).</li><li class="breakAll">https://www.cdc.gov/measles/hcp/index.html (Accessed on December 17, 2021).</li><li><a class="nounderline abstract_t">Hübschen JM, Gouandjika-Vasilache I, Dina J. Measles. Lancet 2022; 399:678.</a></li><li><a class="nounderline abstract_t">Bester JC. Measles and Measles Vaccination: A Review. JAMA Pediatr 2016; 170:1209.</a></li><li><a class="nounderline abstract_t">Richardson M, Elliman D, Maguire H, et al. Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatr Infect Dis J 2001; 20:380.</a></li><li class="breakAll">Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book), 12th ed, Atkinson W, Wolfe C, Hamborsky J (Eds), The Public Health Foundation, Washington, DC 2011.</li><li class="breakAll">Cherry JD. Measles virus. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, et al (Eds), Saunders, Philadelphia 2009. p.2427.</li><li class="breakAll">Bernstein DI, Schiff GM. Measles. In: Infectious Diseases, Gorbach SL, Bartlett JG, Blacklow NR (Eds), WB Saunders, Philadelphia 1998. p.1296.</li><li><a class="nounderline abstract_t">BABBOTT FL Jr, GORDON JE. Modern measles. Am J Med Sci 1954; 228:334.</a></li><li class="breakAll">Griffin DE, Bellini WJ. Measles virus. In: Fields' Virology, Fields BN, Knipe DM, Howley PM (Eds), Lippincott-Raven, Philadelphia 1996. p.1267.</li><li><a class="nounderline abstract_t">Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis 2004; 189 Suppl 1:S4.</a></li><li><a class="nounderline abstract_t">Zenner D, Nacul L. Predictive power of Koplik's spots for the diagnosis of measles. J Infect Dev Ctries 2012; 6:271.</a></li><li><a class="nounderline abstract_t">HUDSON JB, WEINSTEIN L, CHANG TW. Thrombocytopenic purpura in measles. J Pediatr 1956; 48:48.</a></li><li><a class="nounderline abstract_t">Abramson O, Dagan R, Tal A, Sofer S. Severe complications of measles requiring intensive care in infants and young children. Arch Pediatr Adolesc Med 1995; 149:1237.</a></li><li><a class="nounderline abstract_t">Suringa DW, Bank LJ, Ackerman AB. Role of measles virus in skin lesions and Koplik's spots. N Engl J Med 1970; 283:1139.</a></li><li><a class="nounderline abstract_t">Good RA, Zak SJ . Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics 1956; 18:109.</a></li><li><a class="nounderline abstract_t">Naniche D. Human immunology of measles virus infection. Curr Top Microbiol Immunol 2009; 330:151.</a></li><li><a class="nounderline abstract_t">Avota E, Gassert E, Schneider-Schaulies S. Measles virus-induced immunosuppression: from effectors to mechanisms. Med Microbiol Immunol 2010; 199:227.</a></li><li><a class="nounderline abstract_t">Schaffner W, Schluederberg AE, Byrne EB. Clinical epidemiology of sporadic measles in a highly immunized population. N Engl J Med 1968; 279:783.</a></li><li><a class="nounderline abstract_t">Cherry JD, Feigin RD, Lobes LA Jr, et al. Urban measles in the vaccine era: a clinical, epidemiologic, and serologic study. J Pediatr 1972; 81:217.</a></li><li><a class="nounderline abstract_t">Bolotin S, Osman S, Hughes SL, et al. In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis. J Infect Dis 2022; 226:1127.</a></li><li class="breakAll">MMWR. Measles Outbreak in a Highly Vaccinated Population — Israel.
July–August 2017. https://www.cdc.gov/mmwr/volumes/67/wr/pdfs/mm6742a4-H.pdf (Accessed on October 26, 2018).</li><li><a class="nounderline abstract_t">Hickman CJ, Hyde TB, Sowers SB, et al. Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals. J Infect Dis 2011; 204 Suppl 1:S549.</a></li><li><a class="nounderline abstract_t">Rosen JB, Rota JS, Hickman CJ, et al. Outbreak of measles among persons with prior evidence of immunity, New York City, 2011. Clin Infect Dis 2014; 58:1205.</a></li><li><a class="nounderline abstract_t">Leuridan E, Hens N, Hutse V, et al. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ 2010; 340:c1626.</a></li><li><a class="nounderline abstract_t">Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036.</a></li><li><a class="nounderline abstract_t">Griffin DE, Pan CH. Measles: old vaccines, new vaccines. Curr Top Microbiol Immunol 2009; 330:191.</a></li><li><a class="nounderline abstract_t">Polack FP, Hoffman SJ, Crujeiras G, Griffin DE. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 2003; 9:1209.</a></li><li class="breakAll">Gershon AA. Measles virus (rubeola). In: Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, New York City 1995. p.1519.</li><li><a class="nounderline abstract_t">Nandy R, Handzel T, Zaneidou M, et al. Case-fatality rate during a measles outbreak in eastern Niger in 2003. Clin Infect Dis 2006; 42:322.</a></li><li><a class="nounderline abstract_t">Beckford AP, Kaschula RO, Stephen C. Factors associated with fatal cases of measles. A retrospective autopsy study. S Afr Med J 1985; 68:858.</a></li><li><a class="nounderline abstract_t">Greenberg BL, Sack RB, Salazar-Lindo E, et al. Measles-associated diarrhea in hospitalized children in Lima, Peru: pathogenic agents and impact on growth. J Infect Dis 1991; 163:495.</a></li><li><a class="nounderline abstract_t">Ben-Chetrit E, Oster Y, Jarjou'i A, et al. Measles-related hospitalizations and associated complications in Jerusalem, 2018-2019. Clin Microbiol Infect 2020; 26:637.</a></li><li class="breakAll">James Cherry. Measles. In: Textbook of Pediatric Infectious Diseases, 8th, Feigin and Cherry (Ed), Elsevier, 2017. p.1763.</li><li><a class="nounderline abstract_t">Mina MJ, Metcalf CJ, de Swart RL, et al. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science 2015; 348:694.</a></li><li><a class="nounderline abstract_t">Szállási A. [Kálmán Tellyesniczky (1868-1932)]. Orv Hetil 1978; 119:2827.</a></li><li><a class="nounderline abstract_t">Griffin DE. Measles virus-induced suppression of immune responses. Immunol Rev 2010; 236:176.</a></li><li><a class="nounderline abstract_t">Coughlin MM, Bellini WJ, Rota PA. Contribution of dendritic cells to measles virus induced immunosuppression. Rev Med Virol 2013; 23:126.</a></li><li><a class="nounderline abstract_t">Mina MJ, Kula T, Leng Y, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science 2019; 366:599.</a></li><li><a class="nounderline abstract_t">Petrova VN, Sawatsky B, Han AX, et al. Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles. Sci Immunol 2019; 4.</a></li><li><a class="nounderline abstract_t">Quiambao BP, Gatchalian SR, Halonen P, et al. Coinfection is common in measles-associated pneumonia. Pediatr Infect Dis J 1998; 17:89.</a></li><li><a class="nounderline abstract_t">Ross LA, Kim KS, Mason WH Jr, Gomperts E. Successful treatment of disseminated measles in a patient with acquired immunodeficiency syndrome: consideration of antiviral and passive immunotherapy. Am J Med 1990; 88:313.</a></li><li><a class="nounderline abstract_t">Zeng SZ, Zhang B, Zhang Y, et al. Identification of 12 Cases of Acute Measles Encephalitis Without Rash. Clin Infect Dis 2016; 63:1630.</a></li><li><a class="nounderline abstract_t">Johnson RT, Griffin DE, Hirsch RL, et al. Measles encephalomyelitis--clinical and immunologic studies. N Engl J Med 1984; 310:137.</a></li><li><a class="nounderline abstract_t">Griffin DE. Measles virus and the nervous system. Handb Clin Neurol 2014; 123:577.</a></li><li class="breakAll">Adams RD, Victor M, Ropper AH. Multiple sclerosis and allied demyelinative diseases. In: Principles of Neurology, McGraw-Hill (Ed), New York City 1997. p.921.</li><li><a class="nounderline abstract_t">Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 2002; 59:1224.</a></li><li class="breakAll">Dyken PR. Viral diseases of the central nervous system. In: Pediatric Neurology: Principles and Practice, Mosby, St. Louis 1994. p.670.</li><li><a class="nounderline abstract_t">Centers for Disease Control (CDC). Subacute sclerosing panencephalitis surveillance - United States. MMWR Morb Mortal Wkly Rep 1982; 31:585.</a></li><li><a class="nounderline abstract_t">Campbell H, Lopez Bernal J, Bukasa A, et al. A Re-emergence of Subacute Sclerosing Panencephalitis in the United Kingdom. Pediatr Infect Dis J 2023; 42:82.</a></li><li><a class="nounderline abstract_t">Bellini WJ, Rota JS, Lowe LE, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis 2005; 192:1686.</a></li><li><a class="nounderline abstract_t">Wendorf KA, Winter K, Zipprich J, et al. Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. Clin Infect Dis 2017; 65:226.</a></li><li class="breakAll">Bernstein DI, Reuman PD, Schiff GM. Rubeola (measles) and subacute sclerosing panencephalitis virus. In: Infectious Diseases, Gorbach SL, Bartlett JG, Blacklow NR (Eds), WB Saunders, Philadelphia 1998. p.2135.</li><li><a class="nounderline abstract_t">Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol 2007; 36:1334.</a></li><li><a class="nounderline abstract_t">Garg RK. Subacute sclerosing panencephalitis. J Neurol 2008; 255:1861.</a></li><li><a class="nounderline abstract_t">Liko J, Guzman-Cottrill JA, Cieslak PR. Notes from the Field: Subacute Sclerosing Panencephalitis Death - Oregon, 2015. MMWR Morb Mortal Wkly Rep 2016; 65:10.</a></li><li><a class="nounderline abstract_t">Sun X, Burns JB, Howell JM, Fujinami RS. Suppression of antigen-specific T cell proliferation by measles virus infection: role of a soluble factor in suppression. Virology 1998; 246:24.</a></li><li class="breakAll">Adams RD, Victor M, Ropper AH. Viral infections of the central nervous system. In: Principles of Neurology, McGraw-Hill, New York City 1997. p.767.</li><li class="breakAll">Fisch BJ. Periodic complexes. In: Spehlmann's EEG Primer, Fisch BJ (Ed), Elsevier Science, Amsterdam 1991. p.376.</li><li><a class="nounderline abstract_t">Seo YS, Kim HS, Jung DE. 18F-FDG PET and MRS of the early stages of subacute sclerosing panencephalitis in a child with a normal initial MRI. Pediatr Radiol 2010; 40:1822.</a></li><li><a class="nounderline abstract_t">Kagame K, Schwab L. Childhood blindness: dateline Africa. Ophthalmic Surg 1989; 20:128.</a></li><li><a class="nounderline abstract_t">Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA 1992; 267:1237.</a></li><li><a class="nounderline abstract_t">CHRISTENSEN PE, SCHMIDT H, BANG HO, et al. An epidemic of measles in southern Greenland, 1951; measles in virgin soil. III. Measles and tuberculosis. Acta Med Scand 1953; 144:450.</a></li><li><a class="nounderline abstract_t">Arya LS, Taana I, Tahiri C, et al. Spectrum of complications of measles in Afghanistan: a study of 784 cases. J Trop Med Hyg 1987; 90:117.</a></li><li><a class="nounderline abstract_t">Mustafa MM, Weitman SD, Winick NJ, et al. Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. Clin Infect Dis 1993; 16:654.</a></li><li><a class="nounderline abstract_t">Turner A, Jeyaratnam D, Haworth F, et al. Measles-associated encephalopathy in children with renal transplants. Am J Transplant 2006; 6:1459.</a></li><li><a class="nounderline abstract_t">Kannangara S, DeSimone JA, Pomerantz RJ. Attenuation of HIV-1 infection by other microbial agents. J Infect Dis 2005; 192:1003.</a></li><li><a class="nounderline abstract_t">Moss WJ, Monze M, Ryon JJ, et al. Prospective study of measles in hospitalized, human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia. Clin Infect Dis 2002; 35:189.</a></li><li><a class="nounderline abstract_t">Moss WJ, Ryon JJ, Monze M, et al. Suppression of human immunodeficiency virus replication during acute measles. J Infect Dis 2002; 185:1035.</a></li><li class="breakAll">Grivel J, Garca M, Moss W, et al. Chemokine/cytokine modulation by measles virus induces HIV-1 suppression in human lymphoid tissue ex vivo [abstract TuOrA1185]. In: EJournal of the International AIDS Society, XV International AIDS Conference (Bangkok). Geneva: International AIDS Society, 2004.</li><li><a class="nounderline abstract_t">Atmar RL, Englund JA, Hammill H. Complications of measles during pregnancy. Clin Infect Dis 1992; 14:217.</a></li><li><a class="nounderline abstract_t">Siegel M, Fuerst HT. Low birth weight and maternal virus diseases. A prospective study of rubella, measles, mumps, chickenpox, and hepatitis. JAMA 1966; 197:680.</a></li><li class="breakAll">Gershon AA. Chickenpox, measles and mumps. In: Infectious Diseases of the Fetus and Newborn Infant, 6th ed, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2006. p.693.</li><li><a class="nounderline abstract_t">Siegel M, Fuerst HT, Peress NS. Comparative fetal mortality in maternal virus diseases. A prospective study on rubella, measles, mumps, chicken pox and hepatitis. N Engl J Med 1966; 274:768.</a></li><li><a class="nounderline abstract_t">Ogbuanu IU, Zeko S, Chu SY, et al. Maternal, fetal, and neonatal outcomes associated with measles during pregnancy: Namibia, 2009-2010. Clin Infect Dis 2014; 58:1086.</a></li><li><a class="nounderline abstract_t">Bellini WJ, Helfand RF. The challenges and strategies for laboratory diagnosis of measles in an international setting. J Infect Dis 2003; 187 Suppl 1:S283.</a></li><li class="breakAll">Mason EO. Use of the serology laboratory. In: Textbook of Pediatric Infectious Diseases, 5th ed, Feigin RD, Cherry JD, Demmler GJ, et al (Eds), WB Saunders, Philadelphia 2004. p.3318.</li><li><a class="nounderline abstract_t">Jenkerson SA, Beller M, Middaugh JP, Erdman DD. False positive rubeola IgM tests. N Engl J Med 1995; 332:1103.</a></li><li><a class="nounderline abstract_t">Sowers SB, Anthony K, Mercader S, et al. Performance Characteristics of Six Immunoglobulin M Enzyme-Linked Immunosorbent Assays Used for Laboratory Confirmation of Measles. J Clin Microbiol 2022; 60:e0122722.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Measles (Rubeola): Specimens for Detection of Measles RNA by RT–PCR or Virus Isolation. http://www.cdc.gov/measles/lab-tools/rt-pcr.html (Accessed on February 11, 2015).</li><li class="breakAll">Darmstadt GL, Lane A. Disorders of the mucous membranes. In: Nelson Textbook of Pediatrics, 15th ed, WB Saunders, Philadelphia 1996. p.1888.</li><li><a class="nounderline abstract_t">Laboratory diagnosis of measles infection and monitoring of measles immunization: memorandum from a WHO meeting. Bull World Health Organ 1994; 72:207.</a></li><li><a class="nounderline abstract_t">Garly ML, Balé C, Martins CL, et al. Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau. BMJ 2006; 333:1245.</a></li><li><a class="nounderline abstract_t">Kabra SK, Lodha R, Hilton DJ. Antibiotics for preventing complications in children with measles. Cochrane Database Syst Rev 2008; :CD001477.</a></li><li><a class="nounderline abstract_t">Hussey GD, Klein M. A randomized, controlled trial of vitamin A in children with severe measles. N Engl J Med 1990; 323:160.</a></li><li><a class="nounderline abstract_t">Huiming Y, Chaomin W, Meng M. Vitamin A for treating measles in children. Cochrane Database Syst Rev 2005; :CD001479.</a></li><li><a class="nounderline abstract_t">Lo Vecchio A, Cambriglia MD, Bruzzese D, Guarino A. Vitamin A in Children Hospitalized for Measles in a High-income Country. Pediatr Infect Dis J 2021; 40:723.</a></li><li><a class="nounderline abstract_t">Pal G. Effects of ribavirin on measles. J Indian Med Assoc 2011; 109:666.</a></li><li class="breakAll">Department of Immunization, Vaccines and Biologicals. Response to measles outbreaks in measles mortality reduction settings. World Health Organization, Geneva 2009. http://whqlibdoc.who.int/hq/2009/WHO_IVB_09.03_eng.pdf?ua=1 (Accessed on November 29, 2018).</li><li><a class="nounderline abstract_t">Forni AL, Schluger NW, Roberts RB. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis 1994; 19:454.</a></li><li><a class="nounderline abstract_t">Krasinski K, Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA 1989; 261:2512.</a></li><li><a class="nounderline abstract_t">Roy Moulik N, Kumar A, Jain A, Jain P. Measles outbreak in a pediatric oncology unit and the role of ribavirin in prevention of complications and containment of the outbreak. Pediatr Blood Cancer 2013; 60:E122.</a></li><li><a class="nounderline abstract_t">Jones CE, Dyken PR, Huttenlocher PR, et al. Inosiplex therapy in subacute sclerosing panencephalitis. A multicentre, non-randomised study in 98 patients. Lancet 1982; 1:1034.</a></li><li><a class="nounderline abstract_t">Anlar B, Yalaz K, Oktem F, Köse G. Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon. Neurology 1997; 48:526.</a></li><li><a class="nounderline abstract_t">Gascon GG, International Consortium on Subacute Sclerosing Panencephalitis. Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): international multicenter study. J Child Neurol 2003; 18:819.</a></li><li><a class="nounderline abstract_t">Katz SL, Hinman AR. Summary and conclusions: measles elimination meeting, 16-17 March 2000. J Infect Dis 2004; 189 Suppl 1:S43.</a></li><li class="breakAll">Centers for Disease Control and Prevention. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. http://www.cdc.gov/hicpac/pdf/isolation/Isolation2007.pdf?source=govdelivery (Accessed on February 12, 2015).</li><li><a class="nounderline abstract_t">Gohil SK, Okubo S, Klish S, et al. Healthcare Workers and Post-Elimination Era Measles: Lessons on Acquisition and Exposure Prevention. Clin Infect Dis 2016; 62:166.</a></li></ol></div><div id="topicVersionRevision">Topic 3021 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://apps.who.int/iris/handle/10665/331599" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization. Guide for clinical case management and infection prevention and control during a measles outbreak https://apps.who.int/iris/handle/10665/331599 (Accessed on February 16, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/measles/hcp/index.html" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : https://www.cdc.gov/measles/hcp/index.html (Accessed on December 17, 2021).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35093206" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27695849" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Measles and Measles Vaccination: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11332662" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11332662" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11332662" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11332662" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13197385" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Modern measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13197385" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Modern measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15106083" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The clinical significance of measles: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22421609" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Predictive power of Koplik's spots for the diagnosis of measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13295946" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Thrombocytopenic purpura in measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7581755" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Severe complications of measles requiring intensive care in infants and young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5474350" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Role of measles virus in skin lesions and Koplik's spots.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13335330" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Disturbances in gamma globulin synthesis as experiments of nature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19203109" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Human immunology of measles virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20376484" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Measles virus-induced immunosuppression: from effectors to mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5676221" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical epidemiology of sporadic measles in a highly immunized population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5042481" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Urban measles in the vaccine era: a clinical, epidemiologic, and serologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35417025" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35417025" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21666212" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24585562" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Outbreak of measles among persons with prior evidence of immunity, New York City, 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20483946" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Early waning of maternal measles antibodies in era of measles elimination: longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2230231" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Measles antibody: reevaluation of protective titers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19203111" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Measles: old vaccines, new vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12925847" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12925847" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16392075" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Case-fatality rate during a measles outbreak in eastern Niger in 2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3877996" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Factors associated with fatal cases of measles. A retrospective autopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1995722" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Measles-associated diarrhea in hospitalized children in Lima, Peru: pathogenic agents and impact on growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31499179" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Measles-related hospitalizations and associated complications in Jerusalem, 2018-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31499179" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Measles-related hospitalizations and associated complications in Jerusalem, 2018-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25954009" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/360149" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : [Kálmán Tellyesniczky (1868-1932)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20636817" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Measles virus-induced suppression of immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23280948" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Contribution of dendritic cells to measles virus induced immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31672891" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31672862" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9493801" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Coinfection is common in measles-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1689957" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Successful treatment of disseminated measles in a patient with acquired immunodeficiency syndrome: consideration of antiviral and passive immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27601225" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Identification of 12 Cases of Acute Measles Encephalitis Without Rash.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6197651" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Measles encephalomyelitis--clinical and immunologic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25015505" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Measles virus and the nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25015505" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Measles virus and the nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12391351" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12391351" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6817063" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Subacute sclerosing panencephalitis surveillance - United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36410008" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A Re-emergence of Subacute Sclerosing Panencephalitis in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235165" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28387784" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28387784" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18037676" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Review of the effect of measles vaccination on the epidemiology of SSPE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18846316" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Subacute sclerosing panencephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26765654" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Notes from the Field: Subacute Sclerosing Panencephalitis Death - Oregon, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9656990" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Suppression of antigen-specific T cell proliferation by measles virus infection: role of a soluble factor in suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9656990" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Suppression of antigen-specific T cell proliferation by measles virus infection: role of a soluble factor in suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9656990" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Suppression of antigen-specific T cell proliferation by measles virus infection: role of a soluble factor in suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20237774" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : 18F-FDG PET and MRS of the early stages of subacute sclerosing panencephalitis in a child with a normal initial MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2784557" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Childhood blindness: dateline Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1538561" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Severe measles in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13050348" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : An epidemic of measles in southern Greenland, 1951; measles in virgin soil. III. Measles and tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3586091" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Spectrum of complications of measles in Afghanistan: a study of 784 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8323578" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16686771" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Measles-associated encephalopathy in children with renal transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16107952" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Attenuation of HIV-1 infection by other microbial agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12087526" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prospective study of measles in hospitalized, human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11930312" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Suppression of human immunodeficiency virus replication during acute measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11930312" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Suppression of human immunodeficiency virus replication during acute measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571434" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Complications of measles during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5952908" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Low birth weight and maternal virus diseases. A prospective study of rubella, measles, mumps, chickenpox, and hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5952908" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Low birth weight and maternal virus diseases. A prospective study of rubella, measles, mumps, chickenpox, and hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17926883" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Comparative fetal mortality in maternal virus diseases. A prospective study on rubella, measles, mumps, chicken pox and hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24457343" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Maternal, fetal, and neonatal outcomes associated with measles during pregnancy: Namibia, 2009-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12721927" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The challenges and strategies for laboratory diagnosis of measles in an international setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12721927" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The challenges and strategies for laboratory diagnosis of measles in an international setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7898542" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : False positive rubeola IgM tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36409098" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Performance Characteristics of Six Immunoglobulin M Enzyme-Linked Immunosorbent Assays Used for Laboratory Confirmation of Measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36409098" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Performance Characteristics of Six Immunoglobulin M Enzyme-Linked Immunosorbent Assays Used for Laboratory Confirmation of Measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36409098" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Performance Characteristics of Six Immunoglobulin M Enzyme-Linked Immunosorbent Assays Used for Laboratory Confirmation of Measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8205639" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Laboratory diagnosis of measles infection and monitoring of measles immunization: memorandum from a WHO meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060336" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18646073" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Antibiotics for preventing complications in children with measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2194128" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A randomized, controlled trial of vitamin A in children with severe measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235283" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Vitamin A for treating measles in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34250972" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Vitamin A in Children Hospitalized for Measles in a High-income Country.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22480102" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effects of ribavirin on measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22480102" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effects of ribavirin on measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7811865" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2704110" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Measles and measles immunity in children infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23629813" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Measles outbreak in a pediatric oncology unit and the role of ribavirin in prevention of complications and containment of the outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6176821" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Inosiplex therapy in subacute sclerosing panencephalitis. A multicentre, non-randomised study in 98 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9040751" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14736075" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): international multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15106088" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Summary and conclusions: measles elimination meeting, 16-17 March 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15106088" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Summary and conclusions: measles elimination meeting, 16-17 March 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26354971" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Healthcare Workers and Post-Elimination Era Measles: Lessons on Acquisition and Exposure Prevention.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
